[시장보고서]항혈관내피성장인자 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 제품별, 질환별, 최종사용자별, 지역별, 경쟁별 세분화(2020-2030년)

항혈관내피성장인자 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 제품별, 질환별, 최종사용자별, 지역별, 경쟁별 세분화(2020-2030년)

Anti-Vascular Endothelial Growth Factor Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Disease, By End Users, By Region and Competition, 2020-2030F

상품코드 : 1886400

리서치사 : TechSci Research

발행일 : 2025년 12월

페이지 정보 : 영문 185 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,708,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,199,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,926,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 항혈관내피성장인자(VEGF) 치료제 시장은 2024년에 143억 8,000만 달러로 평가되며, 2030년까지 CAGR 3.65%로 성장하며, 178억 3,000만 달러에 달할 것으로 예측됩니다. 항혈관내피성장인자(VEGF) 치료제는 신규 혈관 형성을 억제하도록 설계된 생물제제의 일종으로, 이 과정은 다양한 질환의 진행에 있으며, 매우 중요합니다. 이 치료법은 주로 노화성 황반변성, 당뇨성 황반부종 등 안과 질환과 여러 암종 치료에 활용되고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	143억 8,000만 달러
시장 규모 : 2030년	178억 3,000만 달러
CAGR : 2025-2030년	3.65%
가장 빠르게 성장하는 부문	Eylea
최대 시장	북미

주요 시장 성장 촉진요인

안과 질환, 특히 노화성 황반변성(AMD)과 당뇨병성 황반부종(DME)의 전 세계 유병률 증가는 항혈관내피세포성장인자(VEGF) 치료제 시장의 큰 원동력이 되고 있습니다. 이들 질환은 전 세계에서 실명 및 심각한 시력 장애의 주요 원인으로, 효과적이고 지속적인 약리학적 개입이 필요한 질환입니다.

주요 시장 과제

세계 항혈관내피세포증식인자 치료제 시장은 여러 기존 생물제제의 특허 만료가 임박함에 따라 심각한 문제에 직면해 있습니다. 이러한 상황은 바이오시밀러의 경쟁을 심화시킬 것으로 예상되며, 이는 오리지널 제조업체 시장 역학에 직접적인 영향을 미칠 것으로 보입니다.

주요 시장 동향

세계 항혈관내피성장인자(VEGF) 치료제 시장은 항 VEGF 바이오시밀러 시장 침투 확대에 의해 크게 형성되고 있습니다. 이러한 추세는 특히 주요 바이오의약품의 특허가 만료되는 상황에서 비용 효율성 향상과 중요한 치료제에 대한 환자 접근성 확대가 필수적이기 때문에 더욱 가속화되고 있습니다.

영문목차

The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market, valued at USD 14.38 Billion in 2024, is projected to experience a CAGR of 3.65% to reach USD 17.83 Billion by 2030. Anti-vascular endothelial growth factor (VEGF) therapeutics are a class of biological drugs designed to inhibit the formation of new blood vessels, a process crucial in the progression of various diseases. These therapies are predominantly utilized in the treatment of ophthalmic conditions, such as age-related macular degeneration and diabetic macular edema, as well as several types of cancer.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 14.38 Billion
Market Size 2030	USD 17.83 Billion
CAGR 2025-2030	3.65%
Fastest Growing Segment	Eylea
Largest Market	North America

Key Market Drivers

The escalating global prevalence of ophthalmic diseases, particularly age-related macular degeneration (AMD) and diabetic macular edema (DME), serves as a substantial impetus for the anti-vascular endothelial growth factor therapeutics market. These debilitating conditions, which are leading causes of blindness and severe vision impairment worldwide, necessitate effective and sustained pharmacological intervention. Enhanced diagnostic capabilities and improved patient access to ophthalmological care contribute to a larger identified patient pool requiring treatment.

Key Market Challenges

The global anti-vascular endothelial growth factor therapeutics market faces a significant challenge from the impending patent expirations of several established biological drugs. This scenario is expected to intensify biosimilar competition, which directly influences the market dynamics for originator manufacturers. As biosimilar versions become available, they enter the market at considerably lower prices to gain market share. This increased competition drives down the average selling prices across the entire product class.

Key Market Trends

The Global Anti-Vascular Endothelial Growth Factor (VEGF) Therapeutics Market is significantly shaped by the expanding market penetration of anti-VEGF biosimilars. This trend is driven by the imperative to enhance cost-effectiveness and broaden patient access to critical therapies, particularly as key originator biologics face patent expirations. Biosimilars introduce robust price competition, thereby fostering greater affordability and increasing the overall volume of anti-VEGF treatments dispensed.

Key Market Players

F. Hoffmann-La Roche Ltd.
Biogen MA Inc.
Pfizer Inc.
Coherus BioSciences, Inc.
Amgen Inc.
Viatris Inc.
Bausch Health Companies Inc.
Novartis AG
Regeneron Pharmaceuticals Inc.

Report Scope:

In this report, the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Product:

Eylea
Lucentis
Beovu

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Disease:

Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-related Macular Degeneration

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By End Users:

Hospitals & Clinics
Ambulatory Care centers
Others

Anti-Vascular Endothelial Growth Factor Therapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anti-Vascular Endothelial Growth Factor Therapeutics Market.

Available Customizations:

Global Anti-Vascular Endothelial Growth Factor Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Eylea, Lucentis, Beovu)
- 5.2.2. By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration)
- 5.2.3. By End Users (Hospitals & Clinics, Ambulatory Care centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Disease
- 6.2.3. By End Users
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Disease
    - 6.3.1.2.3. By End Users
- 6.3.2. Canada Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Disease
    - 6.3.2.2.3. By End Users
- 6.3.3. Mexico Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Disease
    - 6.3.3.2.3. By End Users

7. Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Disease
- 7.2.3. By End Users
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Disease
    - 7.3.1.2.3. By End Users
- 7.3.2. France Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Disease
    - 7.3.2.2.3. By End Users
- 7.3.3. United Kingdom Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Disease
    - 7.3.3.2.3. By End Users
- 7.3.4. Italy Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Disease
    - 7.3.4.2.3. By End Users
- 7.3.5. Spain Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Disease
    - 7.3.5.2.3. By End Users

8. Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Disease
- 8.2.3. By End Users
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Disease
    - 8.3.1.2.3. By End Users
- 8.3.2. India Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Disease
    - 8.3.2.2.3. By End Users
- 8.3.3. Japan Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Disease
    - 8.3.3.2.3. By End Users
- 8.3.4. South Korea Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Disease
    - 8.3.4.2.3. By End Users
- 8.3.5. Australia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Disease
    - 8.3.5.2.3. By End Users

9. Middle East & Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Disease
- 9.2.3. By End Users
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Disease
    - 9.3.1.2.3. By End Users
- 9.3.2. UAE Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Disease
    - 9.3.2.2.3. By End Users
- 9.3.3. South Africa Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Disease
    - 9.3.3.2.3. By End Users

10. South America Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Disease
- 10.2.3. By End Users
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Disease
    - 10.3.1.2.3. By End Users
- 10.3.2. Colombia Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Disease
    - 10.3.2.2.3. By End Users
- 10.3.3. Argentina Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Disease
    - 10.3.3.2.3. By End Users

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Anti-Vascular Endothelial Growth Factor Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. F. Hoffmann-La Roche Ltd.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Biogen MA Inc.
15.3. Pfizer Inc.
15.4. Coherus BioSciences, Inc.
15.5. Amgen Inc.
15.6. Viatris Inc.
15.7. Bausch Health Companies Inc.
15.8. Novartis AG
15.9. Regeneron Pharmaceuticals Inc.

한글목차

주요 시장 성장 촉진요인

주요 시장 과제

주요 시장 동향

목차

제1장 개요

제2장 조사 방법

제3장 개요

제4장 고객의 소리

제5장 세계의 항혈관내피성장인자 치료제 시장 전망

제6장 북미의 항혈관내피성장인자 치료제 시장 전망

제7장 유럽의 항혈관내피성장인자 치료제 시장 전망

제8장 아시아태평양의 항혈관내피성장인자 치료제 시장 전망

제9장 중동 및 아프리카의 항혈관내피성장인자 치료제 시장 전망

제10장 남미의 항혈관내피성장인자 치료제 시장 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계의 항혈관내피성장인자 치료제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

제15장 경쟁 구도

제16장 전략적 제안

제17장 조사회사 소개·면책사항